NO20074654L - Lenteviral-vektorer og deres anvendelse - Google Patents
Lenteviral-vektorer og deres anvendelseInfo
- Publication number
- NO20074654L NO20074654L NO20074654A NO20074654A NO20074654L NO 20074654 L NO20074654 L NO 20074654L NO 20074654 A NO20074654 A NO 20074654A NO 20074654 A NO20074654 A NO 20074654A NO 20074654 L NO20074654 L NO 20074654L
- Authority
- NO
- Norway
- Prior art keywords
- vectors
- lentiviral vectors
- gene
- sequences
- lentivirus vectors
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 5
- 241000713666 Lentivirus Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65338605P | 2005-02-16 | 2005-02-16 | |
| US66031005P | 2005-03-10 | 2005-03-10 | |
| US68205905P | 2005-05-18 | 2005-05-18 | |
| US72376805P | 2005-10-05 | 2005-10-05 | |
| PCT/US2006/005431 WO2006089001A2 (en) | 2005-02-16 | 2006-02-16 | Lentiviral vectors and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20074654L true NO20074654L (no) | 2007-11-16 |
Family
ID=36917037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20074654A NO20074654L (no) | 2005-02-16 | 2007-09-12 | Lenteviral-vektorer og deres anvendelse |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080254008A1 (enExample) |
| EP (2) | EP1858332A4 (enExample) |
| JP (2) | JP2008538174A (enExample) |
| KR (1) | KR20070114157A (enExample) |
| AU (1) | AU2006214278C1 (enExample) |
| CA (1) | CA2597928A1 (enExample) |
| MX (1) | MX2007010008A (enExample) |
| NO (1) | NO20074654L (enExample) |
| WO (1) | WO2006089001A2 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7862810B2 (en) * | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| RU2008143555A (ru) | 2006-04-06 | 2010-06-27 | Бёрингер Ингельхайм Интернациональ Гмбх (De) | Тиазолилдигидроиндазолы |
| WO2008044869A1 (en) | 2006-10-10 | 2008-04-17 | Viromed Co., Ltd. | Expression vectors with improved safety |
| WO2008075911A1 (en) * | 2006-12-20 | 2008-06-26 | Avixgen Inc. | Vector for expressing nc protein of hiv and method for producing nc protein using the same |
| WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| WO2010051521A1 (en) * | 2008-10-31 | 2010-05-06 | Lentigen Corporation | Cell therapy product for the treatment of hiv infection |
| EP2405945A4 (en) * | 2009-03-13 | 2012-09-12 | Lentigen Corp | NON-INTEGRAL RETROVIRAL VECTOR VACCINES |
| WO2011066578A1 (en) * | 2009-11-30 | 2011-06-03 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer |
| US20120260355A1 (en) * | 2009-12-22 | 2012-10-11 | The Trustees Of Columbia University In The City Of New York | Method for Evaluating Inhibitory Polynucleotide Efficiency and Efficacy |
| JP6143231B2 (ja) * | 2011-06-10 | 2017-06-07 | ブルーバード バイオ， インコーポレイテッド | 副腎脳白質ジストロフィおよび副腎脊髄神経障害のための遺伝子療法ベクター |
| ES2717876T3 (es) * | 2011-12-12 | 2019-06-26 | Childrens Hospital Philadelphia | Sistema de producción de un vector lentiviral a gran escala comercial y vectores así producidos |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| EP3137100B1 (en) | 2014-04-15 | 2023-12-20 | University Of Virginia Patent Foundation | Isolated t cell receptors and methods of use therefor |
| ES2813437T3 (es) * | 2014-07-11 | 2021-03-23 | Celgene Corp | Métodos para mejorar la eficiencia de la transducción vectorial en linfocitos T |
| WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
| EP3212788A2 (en) | 2014-10-27 | 2017-09-06 | The Broad Institute, Inc. | Compositions, methods and use of synthetic lethal screening |
| WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
| WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
| CR20200476A (es) | 2015-05-20 | 2020-12-02 | Dana Farber Cancer Inst Inc | ANTÍGENOS COMPARTIDOS (Divisional 2017-0584) |
| EP3319631A4 (en) | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | HIV PREMUNICATION AND IMMUNOTHERAPY |
| DK3356524T3 (da) * | 2015-09-30 | 2021-11-15 | Vycellix Inc | Forøget genlevering til naturlige dræberceller, hæmatopoietiske stamceller og makrofager |
| WO2017059241A1 (en) | 2015-10-02 | 2017-04-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lentiviral protein delivery system for rna-guided genome editing |
| WO2017079269A1 (en) | 2015-11-04 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Igf2bp1 and/or igf2bp3 for treatment |
| RU2639539C2 (ru) * | 2015-12-29 | 2017-12-21 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Репортерная система на основе лентивирусных репортерных конструкций для изучения белок-белковых взаимодействий |
| CA3011529A1 (en) | 2016-01-15 | 2017-07-20 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta t-cells |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| US10888613B2 (en) | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| RS67172B1 (sr) | 2016-03-31 | 2025-09-30 | Biontech Us Inc | Neoantigeni i postupci za njihovu upotrebu |
| EP3446119A1 (en) | 2016-04-18 | 2019-02-27 | The Broad Institute Inc. | Improved hla epitope prediction |
| EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS |
| IL300730A (en) | 2016-07-08 | 2023-04-01 | American Gene Tech Int Inc | Pre-HIV vaccine and immunotherapy |
| JP7176756B2 (ja) | 2016-07-21 | 2022-11-22 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | パーキンソン病を処置するためのウイルスベクター |
| US11529393B2 (en) | 2016-10-10 | 2022-12-20 | The Board Of Trustees Of The Leland Stanford Junior University | Mesenchymal stem cells expressing anti-inflammatory cytokines and methods of use |
| KR20190104194A (ko) | 2017-01-07 | 2019-09-06 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| KR102565256B1 (ko) | 2017-02-12 | 2023-08-08 | 바이오엔테크 유에스 인크. | Hla 기반 방법 및 조성물, 및 이들의 용도 |
| BR112019019813A2 (pt) | 2017-03-30 | 2020-04-22 | Univ Queensland | moléculas quiméricas e usos das mesmas |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| EP3654991A1 (en) * | 2017-07-19 | 2020-05-27 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for infectious disease |
| EP4400174A3 (en) | 2017-09-01 | 2024-10-23 | The Francis Crick Institute Limited | Immunoregulatory molecules and uses therefor |
| GB201715052D0 (en) * | 2017-09-19 | 2017-11-01 | Oxford Genetics Ltd | Vectors |
| WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
| ES2951857T3 (es) | 2017-12-22 | 2023-10-25 | Oxford Biomedica Ltd | Vector retroviral |
| RU2697797C2 (ru) * | 2017-12-28 | 2019-08-19 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Генетическая конструкция для индукции пролиферации периферических моноцитов in vitro |
| CA3092372A1 (en) | 2018-02-26 | 2019-08-29 | AnTolRx, Inc. | Tolerogenic liposomes and methods of use thereof |
| WO2020018715A1 (en) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| EP3837355A4 (en) * | 2018-08-16 | 2022-07-06 | Immvira Co., Limited | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS AND MICROBIAL INFECTION |
| US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| WO2020097049A1 (en) | 2018-11-05 | 2020-05-14 | American Gene Technologies International Inc. | Vector system for expressing regulatory rna |
| JP2022513113A (ja) | 2018-11-26 | 2022-02-07 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫寛容のための組成物および方法 |
| US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| MX2021007556A (es) | 2018-12-21 | 2021-09-10 | Biontech Us Inc | Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+. |
| WO2020139796A1 (en) * | 2018-12-23 | 2020-07-02 | Csl Behring L.L.C. | Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome |
| CN109735568A (zh) * | 2019-01-28 | 2019-05-10 | 贵州大学 | 稳定表达fgf-1蛋白细胞株的构建方法 |
| WO2020223205A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
| US20200390718A1 (en) | 2019-05-28 | 2020-12-17 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| AU2021280261A1 (en) | 2020-05-26 | 2023-01-19 | Dionis Therapeutics, Inc. | Nucleic acid artificial mini-proteome libraries |
| MX2022015299A (es) * | 2020-06-02 | 2023-03-13 | Bioplx Inc | Metodos para integracion genomica estable en microorganismos recombinantes. |
| WO2022051555A2 (en) | 2020-09-03 | 2022-03-10 | Rampart Bioscience, Inc. | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
| EP4259206A4 (en) | 2020-12-14 | 2025-07-09 | Biontech Us Inc | TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY |
| TWI758171B (zh) | 2021-04-28 | 2022-03-11 | 沛爾生技醫藥股份有限公司 | 慢病毒包裝系統及使用其以提高宿主細胞之慢病毒產量的方法 |
| WO2023009510A1 (en) * | 2021-07-30 | 2023-02-02 | The Trustees Of Princeton University | Compositions and methods for transfer using cer1 |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| EP4426829A1 (en) | 2021-11-01 | 2024-09-11 | Dana-Farber Cancer Institute, Inc. | Biologically selected nucleic acid artificial mini-proteome libraries |
| US20250009802A1 (en) | 2021-12-16 | 2025-01-09 | Ludwig Institute For Cancer Research Ltd | Antisense transfer vectors and methods of use thereof |
| WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
| WO2024129696A1 (en) | 2022-12-12 | 2024-06-20 | Retromer Therapeutics Corp. | Aav and lentiviral constructs comprising a sorl1 mini-gene for use in treating neurodegenerative diseases |
| CN116656617A (zh) * | 2023-01-03 | 2023-08-29 | 生物岛实验室 | 一种外泌体及其制备方法和应用 |
| WO2024178386A1 (en) | 2023-02-24 | 2024-08-29 | Aarhus Universitet | Methods of treating endosomal trafficking diseases |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US5981276A (en) | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US5817491A (en) | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
| WO1994016060A1 (en) * | 1993-01-11 | 1994-07-21 | The Trustees Of The University Of Pennsylvania | Mutants of hiv for supression of hiv infection |
| US6051427A (en) | 1993-06-11 | 2000-04-18 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5591264A (en) | 1994-03-22 | 1997-01-07 | Sony Corporation | Spin coating device |
| US5750396A (en) | 1995-05-08 | 1998-05-12 | St. Judes Children's Research Hospital | Stable virus packaging cell lines |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5885806A (en) | 1995-11-28 | 1999-03-23 | The Johns Hopkins University School Of Medicine | Methods to prepare conditionally replicating viral vectors |
| US5888767A (en) | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| US6207455B1 (en) * | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| US6531123B1 (en) * | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
| JP2001517433A (ja) | 1997-09-24 | 2001-10-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非霊長類レンチウイルスベクターおよびパッケージングシステム |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| AU2495300A (en) * | 1999-01-07 | 2000-07-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Lentivirus vector system |
| US7262049B2 (en) * | 1999-03-16 | 2007-08-28 | Dana-Farber Cancer Institute, Inc. | Pseudotyped lentiviral vectors and uses thereof |
| US6358739B1 (en) | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
| EP1294892B1 (en) * | 2000-06-23 | 2007-10-17 | Wyeth Holdings Corporation | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
| EP1297168A2 (en) * | 2000-07-03 | 2003-04-02 | Gala Design, Inc. | Expression vectors |
| KR100868594B1 (ko) * | 2000-07-03 | 2008-11-13 | 갈라 디자인, 인크. | 다수의 통합 벡터를 함유하는 숙주 세포 |
| US6686159B2 (en) | 2000-08-24 | 2004-02-03 | Sierra Sciences, Inc. | Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression |
| US6627442B1 (en) | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
| US7211247B2 (en) * | 2001-04-09 | 2007-05-01 | University Of Southern California | Lentivirus vectors for gene transfer to alveolar epithelial cells |
| AU2002367024A1 (en) * | 2001-12-21 | 2003-07-30 | Tranzyme, Inc. | Methods and compositions for generating a genetically modified animal using lentiviral vectors |
| US7485291B2 (en) * | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| EP1784506B1 (en) * | 2004-07-21 | 2010-08-25 | Dana-Farber Cancer Institute, Inc. | Lentiviral vectors and uses thereof |
-
2006
- 2006-02-16 EP EP06735210A patent/EP1858332A4/en not_active Withdrawn
- 2006-02-16 KR KR1020077021145A patent/KR20070114157A/ko not_active Withdrawn
- 2006-02-16 MX MX2007010008A patent/MX2007010008A/es active IP Right Grant
- 2006-02-16 CA CA002597928A patent/CA2597928A1/en not_active Abandoned
- 2006-02-16 US US11/884,639 patent/US20080254008A1/en not_active Abandoned
- 2006-02-16 EP EP12176017.7A patent/EP2573185A3/en not_active Withdrawn
- 2006-02-16 WO PCT/US2006/005431 patent/WO2006089001A2/en not_active Ceased
- 2006-02-16 AU AU2006214278A patent/AU2006214278C1/en not_active Ceased
- 2006-02-16 JP JP2007556283A patent/JP2008538174A/ja active Pending
-
2007
- 2007-09-12 NO NO20074654A patent/NO20074654L/no not_active Application Discontinuation
-
2012
- 2012-10-24 JP JP2012234688A patent/JP2013059331A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20080254008A1 (en) | 2008-10-16 |
| CA2597928A1 (en) | 2006-08-24 |
| WO2006089001A2 (en) | 2006-08-24 |
| JP2013059331A (ja) | 2013-04-04 |
| EP1858332A4 (en) | 2011-06-22 |
| AU2006214278C1 (en) | 2012-07-19 |
| AU2006214278A1 (en) | 2006-08-24 |
| AU2006214278B2 (en) | 2012-01-19 |
| EP2573185A2 (en) | 2013-03-27 |
| MX2007010008A (es) | 2008-01-18 |
| KR20070114157A (ko) | 2007-11-29 |
| WO2006089001A3 (en) | 2007-07-12 |
| EP2573185A3 (en) | 2013-06-05 |
| JP2008538174A (ja) | 2008-10-16 |
| EP1858332A2 (en) | 2007-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074654L (no) | Lenteviral-vektorer og deres anvendelse | |
| Merten et al. | Viral vectors for gene therapy and gene modification approaches | |
| BR112021024786A2 (pt) | Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada | |
| JP2012509340A5 (enExample) | ||
| EA200601946A2 (ru) | Антитела, связывающиеся с белками steap-1, и их производные | |
| MX2022010175A (es) | Proteinas de union a flt3 y metodos de uso. | |
| JOP20220079A1 (ar) | بروتين ربط متعددة الخصوصية لمعالجة السرطان | |
| CY1109463T1 (el) | Πεπτιδια kdr και εμβολια που τα περιλαμβανουν | |
| CY1114643T1 (el) | Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων | |
| MX2009000659A (es) | Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso. | |
| EA200800368A1 (ru) | Гликозилированный il-7, получение и применение | |
| MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
| EP3067417A3 (en) | Improved methods for purification of recombinant aav vectors | |
| CY1113560T1 (el) | Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων | |
| NO20071240L (no) | Terapeutiske anvendelser av RTP801 inhibitorer | |
| AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
| EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
| WO2010005704A3 (en) | Novel helper plasmid, defective sindbis viral vectors and methods of use thereof | |
| BRPI0612334A2 (pt) | uso de uma abordagem baseada em galectina-1 direcionada para rnai no tratamento do cÂncer | |
| WO2006138745A3 (en) | Therapeutic peptides and vaccines | |
| DE602007010127D1 (en) | Hiv-impfstoff | |
| DE60325838D1 (de) | Imidazoquinolinamine als adjuvantien für hiv dna vakzine | |
| NO20081541L (no) | Ny sjo-lus vaksine | |
| US10519452B2 (en) | Antiviral agent comprising RNA oligonucleotide | |
| PL1951283T3 (pl) | Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |